Home・Stock List・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Closed

SectorHealthcare

6.2 -0.64

Buy Sell

Overview

Share price change

24h

Current

Min

6.04

Max

6.25

Key metrics
By Trading Economics
Income	36M -3.7M
Sales	16M 66M
EPS	0.01
Profit margin	-5.67
Employees	416
EBITDA	54M 12M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+0.32% upside

Dividends
By Acuity
Next Earnings	5 Nov 2026

Market Stats
By TradingEconomics
Market Cap	970M 2.4B
Previous open	6.84
Previous close	6.2

News Sentiment

By Acuity

100%

323 / 340 Healthcare

Maravai LifeSciences Holdings Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

7 Aug 2026, 20:02 UTC

News

Maravai LifeSciences shares are lower despite Wells Fargo raising the price target to $6.50 following a revenue increase to $51.4 million in Q2.

6 Aug 2026, 23:51 UTC

News

Maravai LifeSciences reported second-quarter revenue of $51.4 million, exceeding expectations, but shares are lower in after-market trading amid a cautious full-year outlook.

3 Aug 2026, 19:46 UTC

Maravai LifeSciences Holdings Inc shares are lower during Monday's session, trading below their 20-day moving average with no specific news to explain the decline.

31 Jul 2026, 19:36 UTC

Maravai LifeSciences Holdings Inc. shares are lower today amid broader market volatility, having previously dropped to a session low before partially recovering.

30 Jul 2026, 16:56 UTC

Maravai LifeSciences Holdings Inc shares are gaining amid broader market recovery, with the S&P 500 advancing as investors engage in bargain hunting.

29 Jul 2026, 20:09 UTC

Maravai LifeSciences Holdings Inc shares declined during Wednesday's session, pulling back from earlier gains amid broader market volatility and rising oil prices.

28 Jul 2026, 18:06 UTC

Maravai LifeSciences Holdings Inc is gaining during Tuesday's session, though it pulled back from earlier highs amid broader market pressure in the tech sector.

24 Jul 2026, 19:36 UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market pressures, reflecting declines in the Nasdaq 100 following disappointing earnings from major tech companies.

23 Jul 2026, 09:01 UTC

Maravai LifeSciences Holdings Inc. shares are lower in pre-market trading, continuing a decline since Wednesday's close without significant recovery.

22 Jul 2026, 19:56 UTC

Maravai LifeSciences Holdings Inc. shares are lower today, retracing from earlier highs amid no specific company news. The stock remains above its 20-day moving average.

21 Jul 2026, 19:56 UTC

News

Maravai LifeSciences' TriLink BioTechnologies secures a patent for CleanCap® technology in China, boosting confidence in RNA-based therapies. Shares are higher since Monday's close.

20 Jul 2026, 20:02 UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market declines. The stock hit a session low earlier but has since recovered slightly.

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

0.32% upside

12 Months Forecast

Average 6.25 USD 0.32%

High 6.5 USD

Low 6 USD

Based on 4 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Maravai LifeSciences Holdings Inc (Class A) - Dist in the past 3 months.

Sentiment

By Acuity

323 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.